Anti-VEGF Benefits All AMD Eyes
Phakic and pseudophakic patients received three monthly loading dose injections of ranizibumab and were then treated on an as needs basis.
At final follow-up, mean BCVA was 0.75 in the phakic group and 0.74 in the pseudophakic group. Both improvements were statistically significant. Central macular thickness decreased significantly in both groups.